Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of SIG-001 in Adult Patients With Severe or Moderately-Severe Haemophilia A Without Inhibitors (SIG-001-121)

NCT04541628 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04541628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of SIG-001 in Adult Patients With Severe or Moderately-Severe Haemophilia A Without Inhibitors (SIG-001-121)
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Terminated
Start date
September 28, 2020
Completion date
January 9, 2023
Enrollment
3 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a